November 9, 2022 — Seven awardees were honored during the American Heart Association Scientific Sessions (AHA 2022). The AHA designates the Distinguished Scientist award for members who have “significantly advanced the understanding of cardiovascular, stroke or brain health.” A summary of the profiles offered by the AHA of its honorees follows.
Tech tools are creating positive change in Cardiac MRI Software Market

Interventional cardiologists know well the phrase “change is the only constant.” This is especially relevant as innovative software solutions continue to emerge which provide value on two impactful fronts — clinical workflow and patient outcomes.

Artificial intelligence-powered alternative data is driving novel and disruptive market research opportunities at a staggering clip amid category growth forecasts, prompting industries of every size and sort to capitalize on this strategy that’s ever evolving and innovating 

Numerous indicators make clear that the next five years will usher in extreme transformation for a multitude of industries and sectors as well as the global economy at large. This begs the question: what is driving such significant and rapid change? This big question just might be answered in two words: alternative data. 

Reflecting back, 2022 has been a productive year. It brought with it many changes and challenges, but also brought back some of the normalcy the industry has not experienced over the past two years since the onslaught of the pandemic.

November 8, 2022 — Genomic-based therapies for cardiovascular disease are emerging fast in research, and could soon be used regularly in hospitals and practices around the world — changing future treatment, said Ann Marie Schmidt, MD, FAHA.

November 8, 2022 — After hospital discharge for heart failure, people treated with either loop diuretic medication furosemide or torsemide had similar death and hospitalization rates, according to late-breaking science researchpresented today at the

November 8, 2022 — A single IV infusion of NTLA-2001, a novel CRISPR/Cas9-based gene editing therapy, significantly reduced circulating transthyretin (TTR) protein levels in patients with ATTR amyloid cardiomyopathy, a progressive and fatal cause of heart failure, according to late-breaking research presented today at the American Heart Association’s Scientific Sessions 2022. The meeting, held in person in Chicago and virtually, Nov.

November 8, 2022 — Fujifilm Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, announced the U.S.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now